Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine PEP for COVID-19 in HCWs
NCT04438837Unknown
- Sponsor
- Rambam Health Care Campus
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Number of participants who develop clinical signs compatible with COVID 19 at 14 days. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04438837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438837.